Stockreport

Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF CEO: Naoki Okamura , "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with meno [Read more]